Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma
- 15 November 1989
- Vol. 64 (10) , 2010-2013
- https://doi.org/10.1002/1097-0142(19891115)64:10<2010::aid-cncr2820641007>3.0.co;2-o
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.Journal of Clinical Oncology, 1989
- Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.Journal of Clinical Oncology, 1986
- A Comparison of Three Chemotherapeutic Regimens in the Treatment of Advanced Pancreatic and Gastric CarcinomaJAMA, 1985
- Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patientsCancer Treatment Reviews, 1983
- High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcomaCancer Treatment Reviews, 1983
- Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-d in advanced measurable pancreatic carcinoma.A gastrointestinal tumor study group reportCancer, 1978
- Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5‐fluorouracil and streptozotocin plus cyclophosphamideCancer, 1977